{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03381326",
      "OrgStudyIdInfo": {
        "OrgStudyId": "IRSTB030"
      },
      "Organization": {
        "OrgFullName": "Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.",
      "OfficialTitle": "Biomarkers Study: Circulating Tumor Cells (CTC), Free DNA, Stem Cells and Epithelial-mesenchymal-transition (EMT) Related Antigens as Biomarkers of Activity of Cabazitaxel in Castration-resistant Prostate Cancer (CRPC): a Proof of Concept.",
      "Acronym": "IRSTB030"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2021",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 15, 2014",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "October 2019",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2021",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "December 18, 2017",
      "StudyFirstSubmitQCDate": "December 18, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 22, 2017",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "February 25, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 26, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Identification of biomarkers (Circulating Tumor Cells (CTC), free DNA, Stem Cells and EMT-related antigens) that may be predictive of outcome of activity of cabazitaxel treatment in castration-resistant prostate cancer.",
      "DetailedDescription": "Circulating Tumor Cells, free DNA, Stem Cells and EMT-related antigens as biomarkers of activity of cabazitaxel in castration-resistant prostate cancer\n\nPrimary objectives: To evaluate the prognostic role of response of the copy number of androgen receptor (AR) and Phosphatase and tensin homolog (PTEN) and AR-V7 and other gene expression biomarkers in CTC and the investigators will compare these results with those obtained in plasma cell free DNA and RNA.\n\nEligible patients must have histologically or cytologically confirmed prostate cancer or unequivocal increased PSA . Metastatic and/or inoperable disease and received prior therapy with docetaxel and candidate to cabazitaxel treatment.\n\nAll patients receive cabazitaxel at standard schedule 25 mg/m2 q21. Blood sample will be collected for CTC evaluation at baseline, after the first cycle of therapy (optional), at first radiological evaluation (after 3 months), at disease progression (optional) or after 9-12 months of treatment for patients who did not show disease progression (optional). Disease progression defined according to Prostate Cancer Working Group 2 (PCWG2) criteria. On blood samples from Castration-Resistant Prostate Cancer (CRPC) patients the investigators will investigate the presence of the previously presented CTC, DNA and RNA free markers.\n\nAs an option, it will be possible to require a sample of the tumor collected during prostate surgery or during the biopsy.\n\nAll patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Prostate Cancer",
          "Metastatic Cancer",
          "Castration-resistant Prostate Cancer",
          "Circulating Tumor Cells"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "circulating tumor cells",
          "Castration-resistant Prostate Cancer",
          "cabazitaxel",
          "biomarker",
          "free DNA",
          "stem cells",
          "EMT related antigens"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Observational",
      "PatientRegistry": "No",
      "DesignInfo": {
        "DesignObservationalModelList": {
          "DesignObservationalModel": [
            "Case-Only"
          ]
        },
        "DesignTimePerspectiveList": {
          "DesignTimePerspective": [
            "Prospective"
          ]
        }
      },
      "BioSpec": {
        "BioSpecRetention": "Samples With DNA",
        "BioSpecDescription": "blood samples and FFPE samples"
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "94",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Procedure",
            "InterventionName": "blood and FFPE sample collection",
            "InterventionDescription": "blood sample and Formalin-fixed paraffin-embedded (FFPE) sample collection"
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Progression free survival (PFS)",
            "PrimaryOutcomeDescription": "time between the start of cabazitaxel and the ﬁrst date of progression as measured by PCWG-2 criteria.",
            "PrimaryOutcomeTimeFrame": "36 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Overall survival (OS)",
            "SecondaryOutcomeDescription": "The overall survival will be calculated from date of the start of cabazitaxel to death",
            "SecondaryOutcomeTimeFrame": "36 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAbility to understand and the willingness to sign a written informed consent document\nMale aged >18 years with metastatic castration-resistant disease with documented clinical (imaging) and/or biochemical progression (PSA increasing values) during or after a previous docetaxel-based chemotherapy\nPatients must have metastatic and/or inoperable disease\nPatients must have received prior therapy docetaxel based and must be candidate to cabazitaxel\nLife expectancy of greater than 3 months\nEastern Cooperative Oncology Group (ECOG) performance status <2\n\nExclusion Criteria:\n\nParticipants who are unable to provide informed consent\nParticipation in another clinical trial",
      "HealthyVolunteers": "No",
      "Gender": "Male",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      },
      "StudyPopulation": "Patients with castration-resistant prostate cancer",
      "SamplingMethod": "Probability Sample"
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Ugo De Giorgi",
            "OverallOfficialAffiliation": "Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Ospedali Riuniti Umberto I",
            "LocationCity": "Ancona",
            "LocationState": "AN",
            "LocationCountry": "Italy"
          },
          {
            "LocationFacility": "Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)",
            "LocationCity": "Meldola",
            "LocationState": "FC",
            "LocationZip": "47014",
            "LocationCountry": "Italy"
          },
          {
            "LocationFacility": "IRCCS AOU San martino IST",
            "LocationCity": "Genova",
            "LocationState": "GE",
            "LocationZip": "16132",
            "LocationCountry": "Italy"
          },
          {
            "LocationFacility": "Ospedale Civile degli Infermi",
            "LocationCity": "Rimini",
            "LocationState": "RN",
            "LocationCountry": "Italy"
          },
          {
            "LocationFacility": "Azienda Ospedaliera Cannizzaro",
            "LocationCity": "Catania",
            "LocationCountry": "Italy"
          },
          {
            "LocationFacility": "Ospedale Maggiore della Carità",
            "LocationCity": "Novara",
            "LocationCountry": "Italy"
          },
          {
            "LocationFacility": "Istituto Oncologico del Veneto (IOV) - Università di Padova",
            "LocationCity": "Padova",
            "LocationCountry": "Italy"
          },
          {
            "LocationFacility": "Policlinico Universitario Campus Bio-Medico",
            "LocationCity": "Roma",
            "LocationCountry": "Italy"
          },
          {
            "LocationFacility": "Ospedale Sacro Cuore Don Calabria (Negrar)",
            "LocationCity": "Verona",
            "LocationCountry": "Italy"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "34077818",
            "ReferenceType": "derived",
            "ReferenceCitation": "Conteduca V, Wetterskog D, Castro E, Scarpi E, Romero-Laorden N, Gurioli G, Jayaram A, Lolli C, Schepisi G, Wingate A, Casadei C, Lozano R, Brighi N, Aragón IM, Marin-Aguilera M, Gonzalez-Billalabeitia E, Mellado B, Olmos D, Attard G, De Giorgi U. Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. Eur J Cancer. 2021 Jul;152:49-59. doi: 10.1016/j.ejca.2021.04.025. Epub 2021 May 30."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000011471",
            "ConditionMeshTerm": "Prostatic Neoplasms"
          },
          {
            "ConditionMeshId": "D000009360",
            "ConditionMeshTerm": "Neoplastic Cells, Circulating"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000005834",
            "ConditionAncestorTerm": "Genital Neoplasms, Male"
          },
          {
            "ConditionAncestorId": "D000014565",
            "ConditionAncestorTerm": "Urogenital Neoplasms"
          },
          {
            "ConditionAncestorId": "D000009371",
            "ConditionAncestorTerm": "Neoplasms by Site"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000011469",
            "ConditionAncestorTerm": "Prostatic Diseases"
          },
          {
            "ConditionAncestorId": "D000009362",
            "ConditionAncestorTerm": "Neoplasm Metastasis"
          },
          {
            "ConditionAncestorId": "D000009385",
            "ConditionAncestorTerm": "Neoplastic Processes"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M13487",
            "ConditionBrowseLeafName": "Prostatic Neoplasms",
            "ConditionBrowseLeafAsFound": "Prostate Cancer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11459",
            "ConditionBrowseLeafName": "Neoplasm Metastasis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11457",
            "ConditionBrowseLeafName": "Neoplastic Cells, Circulating",
            "ConditionBrowseLeafAsFound": "Circulating Tumor Cells",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8098",
            "ConditionBrowseLeafName": "Genital Neoplasms, Male",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16467",
            "ConditionBrowseLeafName": "Urogenital Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13485",
            "ConditionBrowseLeafName": "Prostatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11482",
            "ConditionBrowseLeafName": "Neoplastic Processes",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M7833",
            "InterventionBrowseLeafName": "Formaldehyde",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}